A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 270 participants.

Also called NCT07415954

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 270 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07415954
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Croatia, Hungary, Japan, Poland, Portugal, Slovakia, South Korea, Spain, Thailand (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07415954. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-17 (actual); primary completion 2027-09-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
NNC0662-0419
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07415954
Content hash
9cc8de7df255ad5c5cbe27eb53296d0e0b87501998cfceae0bb32a80538f1eda